New Adsorption-Based Biosensors for Cancer Detections and Role of Nano-medicine in Its Prognosis and Inhibition

  • Naheed Bibi
  • Iram Taj Awan
  • Almas Taj Awan


Biosensors can be fabricated using nanomaterials in a certain way, which provides inexpensive, quick, and efficient systems as compared to the heavy traditional instruments used for the early cancer diagnosis. There are ways to prove the credibility, efficiency, and selectivity of such sensors for certain cancer types. Each biosensor serves for only one cancer type and doesn’t serve for more, for example, the biosensor for the pancreatic cancer is different than that for the breast cancer. Once cancer is diagnosed, many kinds of nanoparticles have been known for transporting appropriate anticancer agents to the point of action, based on their chemical modifications and the ligands attached, which facilitate the drug delivery in certain ways. Various factors such as compatibility, bio-distribution, circulation time, degradation, and conditions for bioavailability of drugs are essential in the investigation of the drug delivery process. The selectivity of chemotherapeutics is of great importance and has been achieved through various biological weapons such as monoclonal antibodies specifically designed to recognize and bind certain organic molecules like protein and DNA in cancer cells and hence detected, destroyed, and/or growth inhibited by the immune system. Another approach is to transport the anticancer drugs to the point of activity by conjugating them with the monoclonal antibodies or by incorporation into nanocarriers. Various inhibitors such as tyrosine kinase can inhibit abnormal growth characteristic of cancer and can be used to prevent unwanted growth. Some coordination metal complexes have been known to inhibit cancer growth as well which will also be discussed in the chapter.


  1. 1.
    Wu C-C, Hsu C-W, Chen C-D, Yu C-J, Chang K-P, Tai D-I, Liu H-P, Su W-H, Chang Y-S, Yu J-S (2010) Candidate serological biomarkers for cancer identified from the secretomes of 23 cancer cell lines and the human protein atlas. Mol Cell Proteomics 9:1100–1117. Scholar
  2. 2.
    Henry NL, Hayes DF (2012) Cancer biomarkers. Mol Oncol 6:140–146CrossRefGoogle Scholar
  3. 3.
    Kearney AJ, Murray M (2009) Breast cancer screening recommendations: is mammography the only answer? J Midwifery Womens Health 54:393–400. Scholar
  4. 4.
    Du D, Yan F, Liu S, Ju H (2003) Immunological assay for carbohydrate antigen 19-9 using an electrochemical immunosensor and antigen immobilization in titania sol-gel matrix. J Immunol Methods 283:67–75. Scholar
  5. 5.
    Li L, Zhang L, Yu J, Ge S, Song X (2015) All-graphene composite materials for signal amplification toward ultrasensitive electrochemical immunosensing of tumor marker. Biosens Bioelectron 71:108–114. Scholar
  6. 6.
    Zhang Q, Chen X, Tang Y, Ge L, Guo B, Yao C (2014) Amperometric carbohydrate antigen 19-9 immunosensor based on three dimensional ordered macroporous magnetic Au film coupling direct electrochemistry of horseradish peroxidase. Anal Chim Acta 815:42–50. Scholar
  7. 7.
    Muller PAJ, Vousden KH (2014) Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell 25:304–317. Scholar
  8. 8.
    Oliveira ON, Iost RM, Siqueira JR, Crespilho FN, Caseli L (2014) Nanomaterials for diagnosis: challenges and applications in smart devices based on molecular recognition. ACS Appl Mater Interfaces 6:14745–14766. Scholar
  9. 9.
    Soares AC, Soares JC, Shimizu FM, Melendez ME, Carvalho AL, Oliveira ON (2015) Controlled film architectures to detect a biomarker for pancreatic cancer using impedance spectroscopy. ACS Appl Mater Interfaces 7:25930–25937. Scholar
  10. 10.
    Moraes ML, Rodrigues VC, Soares JC, Ferreira M, de Souza NC, Oliveira ONJ (2014) Immunosensor for HIV-1 diagnostics based on immobilization of the antigenic peptide p24-3 into liposomes. J Nanosci Nanotechnol 14:6638–6645CrossRefGoogle Scholar
  11. 11.
    Raymundo-Pereira PA, Shimizu FM, Coelho D, Piazzeta MHO, Gobbi AL, Machado SAS, Oliveira ONJ (2016) A Nanostructured bifunctional platform for sensing of glucose biomarker in artificial saliva: synergy in hybrid Pt/Au surfaces. Biosens Bioelectron 86:369–376. Scholar
  12. 12.
    Soares JC, Shimizu FM, Soares AC, Caseli L, Ferreira J, Oliveira ON (2015) Supramolecular control in nanostructured film architectures for detecting breast cancer. ACS Appl Mater Interfaces 7:11833–11841. Scholar
  13. 13.
    Soares JC, Soares AC, Pereira PAR, da Rodrigues VC, Shimizu FM, Melendez ME, Scapulatempo Neto C, Carvalho AL, Leite FL, Machado SAS, Oliveira ON (2016) Adsorption according to the Langmuir–Freundlich model is the detection mechanism of the antigen p53 for early diagnosis of cancer. Phys Chem Chem Phys 18:8412–8418. Scholar
  14. 14.
    Luppa PB, Sokoll LJ, Chan DW (2001) Immunosensors--principles and applications to clinical chemistry. Clin Chim Acta 314:1–26CrossRefGoogle Scholar
  15. 15.
    Ishihara S, Labuta J, Van Rossom W, Ishikawa D, Minami K, Hill JP, Ariga K (2014) Porphyrin-based sensor nanoarchitectonics in diverse physical detection modes. Phys Chem Chem Phys 16:9713–9746. Scholar
  16. 16.
    Law W-C, Yong K-T, Baev A, Prasad PN (2011) Sensitivity improved surface plasmon resonance biosensor for cancer biomarker detection based on plasmonic enhancement. ACS Nano 5:4858–4864. Scholar
  17. 17.
    Yang M, Yi X, Wang J, Zhou F (2014) Electroanalytical and surface plasmon resonance sensors for detection of breast cancer and Alzheimer’s disease biomarkers in cells and body fluids. Analyst 139:1814–1825. Scholar
  18. 18.
    Chikkaveeraiah BV, Bhirde AA, Morgan NY, Eden HS, Chen X (2012) Electrochemical immunosensors for detection of cancer protein biomarkers. ACS Nano 6:6546–6561. Scholar
  19. 19.
    Tang CK, Vaze A, Rusling JF (2014) Paper-based electrochemical immunoassay for rapid, inexpensive cancer biomarker protein detection. Anal Methods 6:8878–8881. Scholar
  20. 20.
    Warsinke A, Benkert A, Scheller FW (2000) Electrochemical immunoassays. Fresenius J Anal Chem 366:622–634CrossRefGoogle Scholar
  21. 21.
    Loo L, Capobianco JA, Wu W, Gao X, Shih WY, Shih W-H, Pourrezaei K, Robinson MK, Adams GP (2011) Highly sensitive detection of HER2 extracellular domain in the serum of breast cancer patients by piezoelectric microcantilevers. Anal Chem 83:3392–3397. Scholar
  22. 22.
    Su L, Zou L, Fong C-C, Wong W-L, Wei F, Wong K-Y, Wu RSS, Yang M (2013) Detection of cancer biomarkers by piezoelectric biosensor using PZT ceramic resonator as the transducer. Biosens Bioelectron 46:155–161. Scholar
  23. 23.
    Soares AC, Soares JC, Rodrigues VC, Follmann HDM, Arantes LMRB, Carvalho AC, Melendez ME, Fregnani JHTG, Reis RM, Carvalho AL, Oliveira ONJ (2018) Microfluidic-based genosensor to detect human papillomavirus (HPV16) for head and neck cancer. ACS Appl Mater Interfaces 10:36757–36763. Scholar
  24. 24.
    Xie Y, Chen A, Du D, Lin Y (2011) Graphene-based immunosensor for electrochemical quantification of phosphorylated p53 (S15). Anal Chim Acta 699:44–48. Scholar
  25. 25.
    Wink T, van Zuilen SJ, Bult A, van Bennekom WP (1997) Self-assembled monolayers for biosensors. Analyst 122:43R–50R. Scholar
  26. 26.
    Decher G, Hong JD, Schmitt J (1992) Buildup of ultrathin multilayer films by a self-assembly process: III. Consecutively alternating adsorption of anionic and cationic polyelectrolytes on charged surfaces. Thin Solid Films 210:831–835. Scholar
  27. 27.
    Rydzek G, Ji Q, Li M, Schaaf P, Hill JP, Boulmedais F, Ariga K (2015) Electrochemical nanoarchitectonics and layer-by-layer assembly: from basics to future. Nano Today 10:138–167. Scholar
  28. 28.
    Langmuir I (1918) The adsorption of gases on plane surfaces of glass, mica and platinum. J Am Chem Soc 40:1361–1403. Scholar
  29. 29.
    Jeppu GP, Clement TP (2012) A modified Langmuir-Freundlich isotherm model for simulating pH-dependent adsorption effects. J Contam Hydrol 129–130:46–53. Scholar
  30. 30.
    Raposo M, Oliveira ON (2000) Energies of adsorption of poly(o-methoxyaniline) layer-by-layer films. Langmuir 16:2839–2844. Scholar
  31. 31.
    Bohunicky B, Mousa SA (2010) Biosensors: the new wave in cancer diagnosis. Nanotechnol Sci Appl 4:1–10. Scholar
  32. 32.
    Tothill IE (2009) Biosensors for cancer markers diagnosis. Semin Cell Dev Biol 20:55–62. Scholar
  33. 33.
    Yamaguchi K, Nagano M, Torada N, Hamasaki N, Kawakita M, Tanaka M (2004) Urine diacetylspermine as a novel tumor marker for pancreatobiliary carcinomas. Rinsho Byori 52:336–339PubMedGoogle Scholar
  34. 34.
    Ciambellotti E, Coda C, Lanza E (1993) Determination++ of CA 15-3 in the control of primary and metastatic breast carcinoma. Minerva Med 84:107–112PubMedGoogle Scholar
  35. 35.
    Cook GB, Neaman IE, Goldblatt JL, Cambetas DR, Hussain M, Luftner D, Yeung KK, Chan DW, Schwartz MK, Allard WJ (2001) Clinical utility of serum HER-2/neu testing on the Bayer Immuno 1 automated system in breast cancer. Anticancer Res 21:1465–1470PubMedGoogle Scholar
  36. 36.
    Gann PH, Hennekens CH, Stampfer MJ (1995) A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 273:289–294CrossRefGoogle Scholar
  37. 37.
    Turner APF (2013) Biosensors: sense and sensibility. Chem Soc Rev 42:3184–3196. Scholar
  38. 38.
    Thapa A, Soares AC, Soares JC, Awan IT, Volpati D, Melendez ME, Fregnani JHTG, Carvalho AL, Oliveira ON (2017) Carbon nanotube matrix for highly sensitive biosensors to detect pancreatic cancer biomarker CA19-9. ACS Appl Mater Interfaces 9:25878–25886. Scholar
  39. 39.
    Mavri T, Ben M, Imani R, Junkar I, Valant M, Kralj-igli V (2018) Electrochemical biosensor based on TiO2 nanomaterials for cancer diagnostics. Adv Biomembr Lipid Self-Assembly 27:63–105. Scholar
  40. 40.
    Aschberger K, Gottardo S (2016) Nanomaterials based biosensors for cancer biomarker detection. J Phys Conf Ser 704:1. Scholar
  41. 41.
    Sim J-B, Yang H-H, Lee M-J, Yoon J-B, Choi S-M (2012) Transparent conducting hybrid thin films fabricated by layer-by-layer assembly of single-wall carbon nanotubes and conducting polymers. Appl Phys A Mater Sci Process 108:305–311. Scholar
  42. 42.
    Love JC, Estroff LA, Kriebel JK, Nuzzo RG, Whitesides GM (2005) Self-assembled monolayers of thiolates on metals as a form of nanotechnology. Chem Rev 105:1103–1169CrossRefGoogle Scholar
  43. 43.
    Madou MJ (2002) Fundamentals of microfabrication: the science of miniaturization. CRC Press, Boca Raton, p 49CrossRefGoogle Scholar
  44. 44.
    Soares AC, Soares JC, Shimizu FM, Rodrigues V da C, Awan IT, Melendez ME, Piazzetta MH de O, Gobbi AL, Reis RM, Fregnani JHTG, Carvalho AL, Oliveira ON Jr (2018) A simple architecture with self-assembled monolayers to build immunosensors for detecting the pancreatic cancer biomarker CA19-9. Analyst 143(14):3302–3308. Scholar
  45. 45.
    Allen SJ, Mckay G, Porter JF (2004) Adsorption isotherm models for basic dye adsorption by peat in single and binary component systems. J Colloid Interface Sci 280:322–333. Scholar
  46. 46.
    Limousin G, Gaudet JP, Charlet L, Szenknect S, Barths V, Krimissa M (2007) Sorption isotherms: a review on physical bases, modeling and measurement. Appl Geochem 22:249–275CrossRefGoogle Scholar
  47. 47.
    Ghiaci M, Abbaspur A, Kia R, Seyedeyn-Azad F (2004) Equilibrium isotherm studies for the sorption of benzene, toluene, and phenol onto organo-zeolites and as-synthesized MCM-41. Sep Purif Technol 40:217–229. Scholar
  48. 48.
    Vasanth Kumar K, Sivanesan S (2007) Sorption isotherm for safranin onto rice husk: comparison of linear and non-linear methods. Dyes Pigments 72:130–133. Scholar
  49. 49.
    Soares JC, Iwaki LEO, Soares AC, Rodrigues VC, Melendez ME, Fregnani JHTG, Reis RM, Carvalho AL, Correa DS, Oliveira ON (2017) Immunosensor for pancreatic cancer based on electrospun nanofibers coated with carbon nanotubes or gold nanoparticles. ACS Omega 2:6975–6983. Scholar
  50. 50.
    Riul A, Soto AMG, Mello SV, Bone S, Taylor DM, Mattoso LHC (2003) An electronic tongue using polypyrrole and polyaniline. Synth Met 132:109–116. Scholar
  51. 51.
    Taylor DM, Macdonald AG (1987) AC admittance of the metal/insulator/electrolyte interface. J Phys D Appl Phys 20:1277CrossRefGoogle Scholar
  52. 52.
    Riul AJ, Dantas CAR, Miyazaki CM, Oliveira ONJ (2010) Recent advances in electronic tongues. Analyst 135:2481–2495. Scholar
  53. 53.
    Paulovich FV, Moraes ML, Maki RM, Ferreira M, Oliveira ON Jr, de Oliveira MCF (2011) Information visualization techniques for sensing and biosensing. Analyst 136:1344–1350. Scholar
  54. 54.
    Paulovich FV (2008) Mapeamento de dados multi-dimensionais – integrando mineração e visualização. USP, São PauloCrossRefGoogle Scholar
  55. 55.
    Chabner BA, Roberts TG (2005) Chemotherapy and the war on cancer. Nat Rev Cancer 5:65–72. Scholar
  56. 56.
    Feher J (2017) Cell signaling. In: Quantitative human physiology: an introduction, 2nd edn. Academic Press.
  57. 57.
    Eungdamrong N, Iyengar R (2004) Modeling cell signaling networks. Biol Cell 96:355–362. Scholar
  58. 58.
    Pérez-Herrero E, Fernández-Medarde A (2015) Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm 93:52–79. Scholar
  59. 59.
    Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674. Scholar
  60. 60.
    Wu H-C, Chang D-K, Huang C-T (2006) Targeted therapy for cancer. J Cancer Mol 2(2):57–66Google Scholar
  61. 61.
    Danhier F, Feron O, Préat V (2010) To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 148:135–146. Scholar
  62. 62.
    Hughes B (2010) Antibody–drug conjugates for cancer: poised to deliver? Nat Rev Drug Discov 9:665–667. Scholar
  63. 63.
    Jungbluth AA, Stockert E, Huang HJS, Collins VP, Coplan K, Iversen K, Kolb D, Johns TJ, Scott AM, Gullick WJ, Ritter G, Cohen L, Scanlan MJ, Cavanee WK, Old LJ (2003) A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc Natl Acad Sci 100:639–644. Scholar
  64. 64.
    Scott SD (1998) Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin’s lymphoma. Cancer Pract 6:195–197CrossRefGoogle Scholar
  65. 65.
    Cohen P (1999) The development and therapeutic potential of protein kinase inhibitors. Curr Opin Chem Biol 3:459–465. Scholar
  66. 66.
    Zogakis TG, Libutti SK (2001) General aspects of anti-angiogenesis and cancer therapy. Expert Opin Biol Ther 1:253–275. Scholar
  67. 67.
    Gelperina S, Kisich K, Iseman MD, Heifets L (2005) The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care Med 172:1487–1490. Scholar
  68. 68.
    Duncan R (2006) Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 6:688–701. Scholar
  69. 69.
    Dinndorf PA, Gootenberg J, Cohen MH, Keegan P, Pazdur R (2007) FDA drug approval summary: pegaspargase (Oncaspar(R)) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist 12:991–998. Scholar
  70. 70.
    Masetti R, Pession A (2009) First-line treatment of acute lymphoblastic leukemia with pegasparaginase. Biologics 3:359–368PubMedPubMedCentralGoogle Scholar
  71. 71.
    Canal F, Sanchis J, Vicent MJ (2011) Polymer–drug conjugates as nano-sized medicines. Curr Opin Biotechnol 22:894–900. Scholar
  72. 72.
    Banerjee SS, Aher N, Patil R, Khandare J (2012) Poly(ethylene glycol)-prodrug conjugates: concept, design, and applications. J Drug Deliv 2012:1–17. Scholar
  73. 73.
    Egusquiaguirre SP, Igartua M, Hernández RM, Pedraz JL (2012) Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research. Clin Transl Oncol 14:83–93. Scholar
  74. 74.
    Blanco E, Hsiao A, Mann AP, Landry MG, Meric-Bernstam F, Ferrari M (2011) Nanomedicine in cancer therapy: innovative trends and prospects. Cancer Sci 102:1247–1252. Scholar
  75. 75.
    Malam Y, Loizidou M, Seifalian AM (2009) Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci 30:592–599. Scholar
  76. 76.
    Kono K, Ozawa T, Yoshida T, Ozaki F, Ishizaka Y, Maruyama K, Kojima C, Harada A, Aoshima S (2010) Highly temperature-sensitive liposomes based on a thermosensitive block copolymer for tumor-specific chemotherapy. Biomaterials 31:7096–7105. Scholar
  77. 77.
    Schroeder A, Honen R, Turjeman K, Gabizon A, Kost J, Barenholz Y (2009) Ultrasound triggered release of cisplatin from liposomes in murine tumors. J Control Release 137:63–68. Scholar
  78. 78.
    Simões S, Moreira JN, Fonseca C, Düzgüneş N, de Lima MC (2004) On the formulation of pH-sensitive liposomes with long circulation times. Adv Drug Deliv Rev 56:947–965. Scholar
  79. 79.
    Dicko A, Mayer LD, Tardi PG (2010) Use of nanoscale delivery systems to maintain synergistic drug ratios in vivo. Expert Opin Drug Deliv 7:1329–1341. Scholar
  80. 80.
    May JP, Li S-D (2013) Hyperthermia-induced drug targeting. Expert Opin Drug Deliv 10:511–527. Scholar
  81. 81.
    Nagai H, Okazaki Y, Chew SH, Misawa N, Yamashita Y, Akatsuka S, Ishihara T, Yamashita K, Yoshikawa Y, Yasui H, Jiang L, Ohara H, Takahashi T, Ichihara G, Kostarelos K, Miyata Y, Shinohara H, Toyokuni S (2011) Diameter and rigidity of multiwalled carbon nanotubes are critical factors in mesothelial injury and carcinogenesis. Proc Natl Acad Sci 108:E1330–E1338. Scholar
  82. 82.
    Sinha N, Yeow JT-W (2005) Carbon nanotubes for biomedical applications. IEEE Trans Nanobioscience 4:180–195. Scholar
  83. 83.
    Ali-Boucetta H, Al-Jamal KT, Müller KH, Li S, Porter AE, Eddaoudi A, Prato M, Bianco A, Kostarelos K (2011) Cellular uptake and cytotoxic impact of chemically functionalized and polymer-coated carbon nanotubes. Small 7:3230–3238. Scholar
  84. 84.
    Bianco A, Kostarelos K, Prato M (2011) Making carbon nanotubes biocompatible and biodegradable. Chem Commun 47:10182–10188. Scholar
  85. 85.
    Vardharajula S, Ali SZ, Tiwari PM, Eroğlu E, Vig K, Dennis VA, Singh SR (2012) Functionalized carbon nanotubes: biomedical applications. Int J Nanomedicine 7:5361–5374. Scholar
  86. 86.
    Wu W, Li R, Bian X, Zhu Z, Ding D, Li X, Jia Z, Jiang X, Hu Y (2009) Covalently combining carbon nanotubes with anticancer agent: preparation and antitumor activity. ACS Nano 3:2740–2750. Scholar
  87. 87.
    Ajima K, Murakami T, Mizoguchi Y, Tsuchida K, Ichihashi T, Iijima S, Yudasaka M (2008) Enhancement of in vivo anticancer effects of cisplatin by incorporation inside single-wall carbon nanohorns. ACS Nano 2:2057–2064. Scholar
  88. 88.
    Hampel S, Kunze D, Haase D, Krämer K, Rauschenbach M, Ritschel M, Leonhardt A, Thomas J, Oswald S, Hoffmann V, Büchner B (2008) Carbon nanotubes filled with a chemotherapeutic agent: a nanocarrier mediates inhibition of tumor cell growth. Nanomedicine 3:175–182. Scholar
  89. 89.
    Kam NWS, Liu Z, Dai H (2006) Carbon nanotubes as intracellular transporters for proteins and DNA: an investigation of the uptake mechanism and pathway. Angew Chem Int Ed 45:577–581. Scholar
  90. 90.
    Kostarelos K, Lacerda L, Pastorin G, Wu W, Wieckowski S, Luangsivilay J, Godefroy S, Pantarotto D, Briand J-P, Muller S, Prato M, Bianco A (2007) Cellular uptake of functionalized carbon nanotubes is independent of functional group and cell type. Nat Nanotechnol 2:108–113. Scholar
  91. 91.
    Fabbro C, Ali-Boucetta H, Da Ros T, Kostarelos K, Bianco A, Prato M (2012) Targeting carbon nanotubes against cancer. Chem Commun 48:3911–3926. Scholar
  92. 92.
    Zamboni WC (2008) Concept and clinical evaluation of carrier-mediated anticancer agents. Oncologist 13:248–260. Scholar
  93. 93.
    Zheng S, Chang S, Lu J, Chen Z, Xie L, Nie Y, He B, Zou S, Gu Z (2011) Characterization of 9-nitrocamptothecin liposomes: anticancer properties and mechanisms on hepatocellular carcinoma in vitro and in vivo. PLoS One 6:e21064. Scholar
  94. 94.
    Panyam J, Dali MM, Sahoo SK, Ma W, Chakravarthi SS, Amidon GL, Levy RJ, Labhasetwar V (2003) Polymer degradation and in vitro release of a model protein from poly(d,l-lactide-co-glycolide) nano- and microparticles. J Control Release 92:173–187. Scholar
  95. 95.
    Panyam J, Labhasetwar V (2003) Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 55:329–347. Scholar
  96. 96.
    Feng S-S (2004) Nanoparticles of biodegradable polymers for new-concept chemotherapy. Expert Rev Med Devices 1:115–125. Scholar
  97. 97.
    Langer R, Folkman J (1976) Polymers for the sustained release of proteins and other macromolecules. Nature 263:797–800. Scholar
  98. 98.
    Couvreur P, Kante B, Roland M, Speiser P (1979) Adsorption of antineoplastic drugs to polyalkylcyanoacrylate nanoparticles and their release in calf serum. J Pharm Sci 68:1521–1524. Scholar
  99. 99.
    Ding D, Zhu Z, Liu Q, Wang J, Hu Y, Jiang X, Liu B (2011) Cisplatin-loaded gelatin-poly(acrylic acid) nanoparticles: Synthesis, antitumor efficiency in vivo and penetration in tumors. Eur J Pharm Biopharm 79:142–149. Scholar
  100. 100.
    Wohlfart S, Khalansky AS, Gelperina S, Maksimenko O, Bernreuther C, Glatzel M, Kreuter J (2011) Efficient chemotherapy of rat glioblastoma using doxorubicin-loaded PLGA nanoparticles with different stabilizers. PLoS One 6:e19121. Scholar
  101. 101.
    Danhier F, Lecouturier N, Vroman B, Jérôme C, Marchand-Brynaert J, Feron O, Préat V (2009) Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. J Control Release 133:11–17. Scholar
  102. 102.
    Kim J-H, Kim Y-S, Park K, Kang E, Lee S, Nam HY, Kim K, Park JH, Chi DY, Park R-W, Kim I-S, Choi K, Chan Kwon I (2008) Self-assembled glycol chitosan nanoparticles for the sustained and prolonged delivery of antiangiogenic small peptide drugs in cancer therapy. Biomaterials 29:1920–1930. Scholar
  103. 103.
    Sahoo SK, Ma W, Labhasetwar V (2004) Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. Int J Cancer 112:335–340. Scholar
  104. 104.
    Wang X, Li J, Wang Y, Koenig L, Gjyrezi A, Giannakakou P, Shin EH, Tighiouart M, Chen Z, Nie S, Shin DM (2011) A folate receptor-targeting nanoparticle minimizes drug resistance in a human cancer model. ACS Nano 5:6184–6194. Scholar
  105. 105.
    Steichen SD, Caldorera-Moore M, Peppas NA (2013) A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. Eur J Pharm Sci 48:416–427. Scholar
  106. 106.
    Desai NP, Trieu V, Hwang LY, Wu R, Soon-Shiong P, Gradishar WJ (2008) Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anti-Cancer Drugs 19:899–909. Scholar
  107. 107.
    Frei E (2011) Albumin binding ligands and albumin conjugate uptake by cancer cells. Diabetol Metab Syndr 3:11. Scholar
  108. 108.
    Choi KY, Saravanakumar G, Park JH, Park K (2012) Hyaluronic acid-based nanocarriers for intracellular targeting: interfacial interactions with proteins in cancer. Colloids Surf B Biointerfaces 99:82–94. Scholar
  109. 109.
    Choi KY, Chung H, Min KH, Yoon HY, Kim K, Park JH, Kwon IC, Jeong SY (2010) Self-assembled hyaluronic acid nanoparticles for active tumor targeting. Biomaterials 31:106–114. Scholar
  110. 110.
    Cho H-J, Yoon HY, Koo H, Ko S-H, Shim J-S, Lee J-H, Kim K, Chan Kwon I, Kim D-D (2011) Self-assembled nanoparticles based on hyaluronic acid-ceramide (HA-CE) and Pluronic® for tumor-targeted delivery of docetaxel. Biomaterials 32:7181–7190. Scholar
  111. 111.
    Na K, Bum Lee T, Park K-H, Shin E-K, Lee Y-B, Choi H-K (2003) Self-assembled nanoparticles of hydrophobically-modified polysaccharide bearing vitamin H as a targeted anti-cancer drug delivery system. Eur J Pharm Sci 18:165–173. Scholar
  112. 112.
    Taheri A, Dinarvand R, Atyabi F, Nouri F, Ahadi F, Ghahremani MH, Ostad SN, Borougeni AT, Mansoori P (2011) Targeted delivery of methotrexate to tumor cells using biotin functionalized methotrexate-human serum albumin conjugated nanoparticles. J Biomed Nanotechnol 7:743–753. Scholar
  113. 113.
    Taheri A, Dinarvand R, Nouri FS, Khorramizadeh MR, Borougeni AT, Mansoori P, Atyabi F (2011) Use of biotin targeted methotrexate-human serum albumin conjugated nanoparticles to enhance methotrexate antitumor efficacy. Int J Nanomedicine 6:1863–1874. Scholar
  114. 114.
    Hilgenbrink AR, Low PS (2005) Folate receptor-mediated drug targeting: from therapeutics to diagnostics. J Pharm Sci 94:2135–2146. Scholar
  115. 115.
    Sudimack J, Lee RJ (2000) Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev 41:147–162. Scholar
  116. 116.
    Ponka P, Lok CN (1999) The transferrin receptor: role in health and disease. Int J Biochem Cell Biol 31:1111–1137. Scholar
  117. 117.
    Gu FX, Karnik R, Wang AZ, Alexis F, Levy-Nissenbaum E, Hong S, Langer RS, Farokhzad OC (2007) Targeted nanoparticles for cancer therapy. Nano Today 2:14–21. Scholar
  118. 118.
    Dhar S, Gu FX, Langer R, Farokhzad OC, Lippard SJ (2008) Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci 105:17356–17361. Scholar
  119. 119.
    Brooks PC, Montgomery AMP, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA (1994) Integrin $α$v$β$3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79:1157–1164. Scholar
  120. 120.
    Byrne JD, Betancourt T, Brannon-Peppas L (2008) Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 60:1615–1626. Scholar
  121. 121.
    Rosenberg B, Vancamp L, Trosko JE, Mansour VH (1969) Platinum compounds: a new class of potent antitumour agents. Nature 222:385–386. Scholar
  122. 122.
    Cohen SM, Lippard SJ (2001) Cisplatin: from DNA damage to cancer chemotherapy. Prog Nucleic Acid Res Mol Biol 67:93–130CrossRefGoogle Scholar
  123. 123.
    Johnstone TC, Suntharalingam K, Lippard SJ (2016) The next generation of platinum drugs: targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs. Chem Rev 116:3436–3486. Scholar
  124. 124.
    Kelland LR, Abel G, McKeage MJ, Jones M, Goddard PM, Valenti M, Murrer BA, Harrap KR (1993) Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug. Cancer Res 53:2581–2586PubMedGoogle Scholar
  125. 125.
    Grunicke H, Doppler W, Helliger W, Hermann BJ, Hofmann J, Lindner H, Puschendorf B (1986) Tumor biochemistry as basis for advances in tumor chemotherapy. Arch Geschwulstforsch 56:193–201PubMedGoogle Scholar
  126. 126.
    Zhukova OS, Dobrynin IV (2001) Current results and perspectives of the use of human tumor cell lines for antitumor drug screening. Vopr Onkol 47:706–709PubMedGoogle Scholar
  127. 127.
    Di Pasqua AJ, Goodisman J, Kerwood DJ, Toms BB, Dubowy RL, Dabrowiak JC (2006) Activation of carboplatin by carbonate. Chem Res Toxicol 19:139–149. Scholar
  128. 128.
    Frey U, Ranford JD, Sadler PJ (1993) Ring-opening reactions of the anticancer drug carboplatin: NMR characterization of cis-[Pt(NH3)2(CBDCA-O)(5’-GMP-N7)] in solution. Inorg Chem 32:1333–1340. Scholar
  129. 129.
    Junker A, Roy S, Desroches M-C, Moussay C, Berhoune M, Bellanger A, Fernandez C, Farinotti R (2009) Stability of oxaliplatin solution. Ann Pharmacother 43:390–391CrossRefGoogle Scholar
  130. 130.
    Bancroft DP, Lepre CA, Lippard SJ (1990) Platinum-195 NMR kinetic and mechanistic studies of cis- and trans-diamminedichloroplatinum(II) binding to DNA. J Am Chem Soc 112:6860–6871. Scholar
  131. 131.
    Todd RC, Lippard SJ (2009) Inhibition of transcription by platinum antitumor compounds. Metallomics 1:280–291. Scholar
  132. 132.
    Ziegler CJ, Silverman AP, Lippard SJ (2001) High-throughput synthesis and screening of platinum drug candidates. JBIC 5:774–783CrossRefGoogle Scholar
  133. 133.
    Tannock IF, Rotin D (1989) Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res 49:4373–4384PubMedGoogle Scholar
  134. 134.
    Cleare MJ, Hoeschele JD (1973) Studies on the antitumor activity of group VIII transition metal complexes. Part I. Platinum (II) complexes. Bioinorg Chem 2:187–210. Scholar
  135. 135.
    Farrell N (1996) Current status of structure-activity relationships of platinum anticancer drugs: activation of the trans geometry. Met Ions Biol Syst 32:603–639PubMedGoogle Scholar
  136. 136.
    Pendyala L, Cowens JW, Chheda GB, Dutta SP, Creaven PJ (1988) Identification of cis-dichloro-bis-isopropylamine platinum(II) as a major metabolite of iproplatin in humans. Cancer Res 48:3533–3536PubMedGoogle Scholar
  137. 137.
    Marcon G, Carotti S, Coronnello M, Messori L, Mini E, Orioli P, Mazzei T, Cinellu MA, Minghetti G (2002) Gold(III) complexes with bipyridyl ligands: solution chemistry, cytotoxicity, and DNA binding properties. J Med Chem 45:1672–1677. Scholar
  138. 138.
    Messori L, Orioli P, Tempi C, Marcon G (2001) Interactions of selected gold(III) complexes with calf thymus DNA. Biochem Biophys Res Commun 281:352–360. Scholar
  139. 139.
    Mirabell CK, Johnson RK, Hill DT, Faucette LF, Girard GR, Kuo GY, Sung CM, Crooke ST (1986) Correlation of the in vitro cytotoxic and in vivo antitumor activities of gold(I) coordination complexes. J Med Chem 29:218–223. Scholar
  140. 140.
    McKeage MJ, Berners-Price SJ, Galettis P, Bowen RJ, Brouwer W, Ding L, Zhuang L, Baguley BC (2000) Role of lipophilicity in determining cellular uptake and antitumour activity of gold phosphine complexes. Cancer Chemother Pharmacol 46:343–350. Scholar
  141. 141.
    Berners-Price SJ, Mirabelli CK, Johnson RK, Mattern MR, McCabe FL, Faucette LF, Sung CM, Mong SM, Sadler PJ, Crooke ST (1986) In vivo antitumor activity and in vitro cytotoxic properties of bis[1,2-bis(diphenylphosphino)ethane]gold(I) chloride. Cancer Res 46:5486–5493PubMedGoogle Scholar
  142. 142.
    Rush GF, Smith PF, Alberts DW, Mirabelli CK, Snyder RM, Crooke ST, Sowinski J, Jones HB, Bugelski PJ (1987) The mechanism of acute cytotoxicity of triethylphosphine gold(I) complexes. I. Characterization of triethylphosphine gold chloride-induced biochemical and morphological changes in isolated hepatocytes. Toxicol Appl Pharmacol 90:377–390CrossRefGoogle Scholar
  143. 143.
    Buckley RG, Elsome AM, Fricker SP, Henderson GR, Theobald BR, Parish RV, Howe BP, Kelland LR (1996) Antitumor properties of some 2-[(dimethylamino)methyl]phenylgold(III) complexes. J Med Chem 39:5208–5214. Scholar
  144. 144.
    Cossu F, Matovic Z, Radanovic D, Ponticelli G (1994) Cytotoxic activity of some gold(III) complexes. Farmaco 49:301–302PubMedGoogle Scholar
  145. 145.
    Labbe S, Thiele DJ (1999) Pipes and wiring: the regulation of copper uptake and distribution in yeast. Trends Microbiol 7:500–505CrossRefGoogle Scholar
  146. 146.
    Milne DB (1998) Copper intake and assessment of copper status. Am J Clin Nutr 67:1041S–1045S. Scholar
  147. 147.
    Brewer GJ (2001) Copper control as an antiangiogenic anticancer therapy: lessons from treating Wilson’s disease. Exp Biol Med 226:665–673. Scholar
  148. 148.
    Beraldo H, Gambino D (2004) The wide pharmacological versatility of semicarbazones, thiosemicarba-zones and their metal complexes. Mini Rev Med Chem 4:31–39CrossRefGoogle Scholar
  149. 149.
    Bolos CA, Chaviara AT, Mourelatos D, Iakovidou Z, Mioglou E, Chrysogelou E, Papageorgiou A (2009) Synthesis, characterization, toxicity, cytogenetic and in vivo antitumor studies of 1,1-dithiolate Cu(II) complexes with di-, tri-, tetra- amines and 1,3-thiazoles. Structure–activity correlation. Bioorg Med Chem 17:3142–3151. Scholar
  150. 150.
    Balzarini J, Keyaerts E, Vijgen L, van der Meer F, Stevens M, De Clercq E, Egberink HF, Van Ranst M (2006) Pyridine N-oxide derivatives are inhibitory to the human SARS and feline infectious peritonitis coronavirus in cell culture. J Antimicrob Chemother 57(3):472–481CrossRefGoogle Scholar
  151. 151.
    Dwyer FP, Gyarfas EC, Wright RD, Shulman A (1957) Effect of inorganic complex ions on transmission at a neuromuscular junction. Nature 179:425–426. Scholar
  152. 152.
    Hurtado RR, Harney AS, Heffern MC, Holbrook RJ, Holmgren RA, Meade TJ (2012) Specific inhibition of the transcription factor Ci by a Cobalt(III) schiff base–DNA conjugate. Mol Pharm 9:325–333. Scholar
  153. 153.
    Dhahagani K, Mathan Kumar S, Chakkaravarthi G, Anitha K, Rajesh J, Ramu A, Rajagopal G (2014) Synthesis and spectral characterization of Schiff base complexes of Cu(II), Co(II), Zn(II) and VO(IV) containing 4-(4-aminophenyl)morpholine derivatives: antimicrobial evaluation and anticancer studies. Spectrochim Acta A Mol Biomol Spectrosc 117:87–94. Scholar
  154. 154.
    Ghosh P, Chowdhury AR, Saha SK, Ghosh M, Pal M, Murmu NC, Banerjee P (2015) Synthesis and characterization of redox non-innocent cobalt(III) complexes of a O,N,O donor ligand: radical generation, semi-conductivity, antibacterial and anticancer activities. Inorg Chim Acta 429:99–108. Scholar
  155. 155.
    Raja DS, Bhuvanesh NSP, Natarajan K (2012) A novel water soluble ligand bridged cobalt(II) coordination polymer of 2-oxo-1,2-dihydroquinoline-3-carbaldehyde (isonicotinic) hydrazone: evaluation of the DNA binding, protein interaction, radical scavenging and anticancer activity. Dalton Trans 41:4365–4377. Scholar
  156. 156.
    Schmidt K, Jung M, Keilitz R, Schnurr B, Gust R (2000) Acetylenehexacarbonyldicobalt complexes, a novel class of antitumor drugs. Inorg Chim Acta 306:6–16. Scholar
  157. 157.
    Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231:232–235CrossRefGoogle Scholar
  158. 158.
    Schafer FQ, Buettner GR (2001) Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med 30:1191–1212CrossRefGoogle Scholar
  159. 159.
    Bibi N, Guerra RB, Huamaní LESC, Formiga ALB (2018) Crystal structure, electrochemical and spectroscopic investigation of mer -tris-[2-(1 H-imidazol-2-yl-κN(3))pyrimidine-κN(1)]ruthenium(II) bis(hexafluoridophosphate) trihydrate. Acta Crystallogr Sect E Crystallogr Commun 74:874–877. Scholar
  160. 160.
  161. 161.
    Kratz F, Hartmann M, Keppler B, Messori L (1994) The binding properties of two antitumor ruthenium(III) complexes to apotransferrin. J Biol Chem 269:2581–2588PubMedGoogle Scholar
  162. 162.
    Yano S, Ohi H, Ashizaki M, Obata M, Mikata Y, Tanaka R, Nishioka T, Kinoshita I, Sugai Y, Okura I, Ogura S, Czaplewska JA, Gottschaldt M, Schubert US, Funabiki T, Morimoto K, Nakai M (2012) Syntheses, characterization, and antitumor activities of platinum(II) and palladium(II) complexes with sugar-conjugated triazole ligands. Chem Biodivers 9:1903–1915. Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2020

Authors and Affiliations

  • Naheed Bibi
    • 1
  • Iram Taj Awan
    • 2
  • Almas Taj Awan
    • 3
  1. 1.Department of ChemistryShaheed Benazir Bhutto Women University (SBBWU)PeshawarPakistan
  2. 2.São Carlos Institute of Physics, University of São Paulo (IFSC-USP)São PauloBrazil
  3. 3.Department of ChemistryFederal University of São Carlos (UFSCar)São CarlosBrazil

Personalised recommendations